9594.SR
Unloved QualityAl-Modawat Specialized Medical Company · Healthcare · Saudi Arabia · $75M cap · $17K/day traded
SAR 3.97 +4.5% · close 5 Nov · scored 7 Nov
Unloved Quality: Strong and cheap, but the market has not warmed to it.
As of 7 Nov 2026, the MoatMap Score for Al-Modawat Specialized Medical Company (9594.SR) is 68/100, ranked against 25,000+ stocks in 38 markets (Quality 65, Value 50, Momentum 49, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT AL-MODAWAT SPECIALIZED MEDICAL COMPANY
Read
Al-Modawat Specialized Medical Company operates a general hospital in the Kingdom of Saudi Arabia. The company was founded in 2014 and is headquartered in Muhayil, Saudi Arabia.
FINANCIAL SUMMARY (SAR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 58.6M | 74.3M | 75.5M | 121.8M | 27.7% | 143.4M |
| EPS (SAR) | 0.14 | 0.26 | 0.09 | 0.27 | 23.1% | 0.21 |
| Shares | 71.3M | 71.3M | 71.3M | 71.3M | 0.0% | 71.3M |
| Debt | 2.8M | 2.8M | 11.8M | 5.9M | 28.4% | 53.8M |
| Equity | 31.0M | 39.3M | 77.1M | 88.3M | 41.8% | — |
| Op CF | 5.1M | 13.6M | 10.1M | 4.3M | -5.6% | 22.3M |
| Inv CF | -2.8M | -3.9M | -18.7M | -21.4M | — | — |
| Fin CF | -7.7M | -10.8M | 24.1M | 13.5M | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Swung more than 82% of stocks we rank over the past year (volatility 70% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 9594.SR are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| 9594.SR | Al-Modawat Specialized Medical Company(you) | $75M | 68 |
| 9530.SR | Arabian International Healthcare Holding Company | $87M | 75 |
| 4021.SR | Canadian General Medical Center Complex Company | $92M | 60 |
| 9546.SR | Naba Al Saha Medical Services Company | $123M | 65 |
| 9544.SR | Future Care Trading Co. | $161M | 50 |
| 9627.SR | Twareat Medical Care Company | $96M | 30 |
| 4009.SR | Middle East Healthcare Company | $563M | 73 |
| 4019.SR | Specialized Medical Company | $875M | 69 |
| 4007.SR | Al Hammadi Holding Company | $925M | 68 |
| 4005.SR | National Medical Care Company | $1.2B | 62 |
Peer medians: ROE 13.9% · P/E 16.2x · Gross margin 31.2%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.